BAP1 Protein is a Progression Factor in Malignant Pleural Mesothelioma

被引:61
作者
Arzt, Lisa [1 ]
Quehenberger, Franz [2 ]
Halbwedl, Iris [1 ]
Mairinger, Thomas [3 ]
Popper, Helmut H. [1 ]
机构
[1] Med Univ Graz, Inst Pathol, Res Unit Mol Lung & Pleura Pathol, A-8036 Graz, Austria
[2] Med Univ Graz, Inst Med Informat Stat & Documentat, A-8036 Graz, Austria
[3] HELIOS Klin, Inst Pathol, D-14156 Berlin, Germany
关键词
BRCA1-associated protein1 (BAP1); Malignant pleuralmesothelioma; Asbestos exposure; Overall survival; BRCA1-ASSOCIATED PROTEIN-1; UBIQUITIN HYDROLASE; TUMOR-SUPPRESSOR; CELL-GROWTH; MUTATIONS; GENE; INACTIVATION; PREDISPOSE; MANAGEMENT; APOPTOSIS;
D O I
10.1007/s12253-013-9677-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Human malignant pleural mesothelioma (MPM) is an aggressive cancer due to former asbestos exposure with little knowledge about prognostic factors of outcome and resistance to conventional therapy. BRCA1-associated protein 1 (BAP1) is a tumor suppressor gene that is frequently lost in MPM. Germline mutations of BAP1 predispose to several different tumors including malignant mesothelioma. Our study aimed to clarify if asbestos exposure has an influence on BAP1 expression and if BAP1 expression could be used as a prognostic factor of outcome. An immunohistochemical staining for BAP1 was performed on 123 MPM tissue samples and the expression levels have been correlated with asbestos exposure and overall survival time. BAP1 expression was not associated with asbestos exposure but we detected a significant effect of BAP1 expression on overall survival time - the higher the BAP1 expression (non-mutated BAP1), the shorter the overall survival. BAP1 mutation has been linked to non-asbestos induced familial mesotheliomas, which usually belong to the long survivor group and BAP1 is most probably functioning differently than in sporadic cases. Further investigations need to be performed to characterize the BAP1 mutations and to identify the BAP1 downstream targets in MPM.
引用
收藏
页码:145 / 151
页数:7
相关论文
共 36 条
[1]
Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers [J].
Abdel-Rahman, Mohamed H. ;
Pilarski, Robert ;
Cebulla, Colleen M. ;
Massengill, James B. ;
Christopher, Benjamin N. ;
Boru, Getachew ;
Hovland, Peter ;
Davidorf, Frederick H. .
JOURNAL OF MEDICAL GENETICS, 2011, 48 (12) :856-859
[2]
Malignant pleural mesothelioma: current treatments and emerging drugs [J].
Belli, Carmen ;
Fennell, Dean ;
Giovannini, Monica ;
Gaudino, Giovanni ;
Mutti, Luciano .
EXPERT OPINION ON EMERGING DRUGS, 2009, 14 (03) :423-437
[3]
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma [J].
Bott, Matthew ;
Brevet, Marie ;
Taylor, Barry S. ;
Shimizu, Shigeki ;
Ito, Tatsuo ;
Wang, Lu ;
Creaney, Jenette ;
Lake, Richard A. ;
Zakowski, Maureen F. ;
Reva, Boris ;
Sander, Chris ;
Delsite, Robert ;
Powell, Simon ;
Zhou, Qin ;
Shen, Ronglai ;
Olshen, Adam ;
Rusch, Valerie ;
Ladanyi, Marc .
NATURE GENETICS, 2011, 43 (07) :668-U81
[4]
BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs [J].
Carbone, Michele ;
Ferris, Laura Korb ;
Baumann, Francine ;
Napolitano, Andrea ;
Lum, Christopher A. ;
Flores, Erin G. ;
Gaudino, Giovanni ;
Powers, Amy ;
Bryant-Greenwood, Peter ;
Krausz, Thomas ;
Hyjek, Elizabeth ;
Tate, Rachael ;
Friedberg, Joseph ;
Weigel, Tracey ;
Pass, Harvey I. ;
Yang, Haining .
JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
[5]
Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma [J].
Ceresoli, GL ;
Locati, LD ;
Ferreri, AJM ;
Cozzarini, C ;
Passoni, P ;
Melloni, G ;
Zannini, P ;
Bolognesi, A ;
Villa, E .
LUNG CANCER, 2001, 34 (02) :279-287
[6]
Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas [J].
Dacic, Sanja ;
Kothmaier, Hannelore ;
Land, Stephanie ;
Shuai, Yongli ;
Halbwedl, Iris ;
Morbini, Patrizia ;
Murer, Bruno ;
Comin, Camilla ;
Galateau-Salle, Francoise ;
Demirag, Funda ;
Zeren, Handan ;
Attanoos, Richard ;
Gibbs, Alan ;
Cagle, Philip ;
Popper, Helmut .
VIRCHOWS ARCHIV, 2008, 453 (06) :627-635
[7]
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients [J].
Flores, Raja M. ;
Pass, Harvey I. ;
Seshan, Venkatraman E. ;
Dycoco, Joseph ;
Zakowski, Maureen ;
Carbone, Michele ;
Bains, Manjit S. ;
Rusch, Valerie W. .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2008, 135 (03) :620-+
[8]
Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center [J].
Flores, Raja M. ;
Zakowski, Maureen ;
Venkatraman, Ennapadam ;
Krug, Lee ;
Rosenzweig, Kenneth ;
Dyeoeo, Joseph ;
Lee, Catherine ;
Yeoh, Cindy ;
Bains, Manjit ;
Rusch, Valerie .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (10) :957-965
[9]
Surgical Options in Malignant Pleural Mesothelioma: Extrapleural Pneumonectomy or Pleurectomy/Decortication [J].
Flores, Raja M. .
SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2009, 21 (02) :149-153
[10]
Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma [J].
Gordon, GJ ;
Appasani, K ;
Parcells, JP ;
Mukhopadhyay, NK ;
Jaklitsch, MT ;
Richards, WG ;
Sugarbaker, DJ ;
Bueno, R .
CARCINOGENESIS, 2002, 23 (06) :1017-1024